Companies to play important role in NICE's value-based assessments – by keeping prices down
This article was originally published in Scrip
Executive Summary
Details are emerging on NICE's plans for value-based assessment since the institute released its second consultation document on 27 March, and while it appears that NICE plans to broaden the opportunities for more drugs to be recommended under the new system, they are likely to be contingent on companies squeezing prices for the UK.